Usted buscó: ςύοκιτηβαιδιτνα (Griego - Inglés)

ςύοκιτηβαιδιτνα ςυονε όναβ αλ ςοτα ότσ υοτ όπα ςυολλά ε ςό σαυδνυσ ιακ αίεπαρεθονοΜ
the pharmaceutical sections of the summaries of product characteristics (spcs) have been harmonised, except the sections linked to national marketing authorisations.

, ςεδί αφλυοσ ςετνογάραπ ςύοκιτηβαιδιτνα ςυολλά ε ό σαυδνυσ εσ ιατίειοπο ισηρχ ηνί ροφτε (
glucophage / glucophage forte / dianben / risidon monotherapy does not cause hypoglycaemia and therefore has no effect on the ability to drive or to use machines.

νώκολπιπε νώκιτηβαιδ νωτ ησωίε ίετσαισυοραπ ιεχέ ςατιαίδ αίχυτοπα όπα αρετσύ αίεπαρεθ αιρύκ, ςω ηνί ροφτε ε ςαίεπαρεθ ιεχύτ νυοχέ ιοίοπο ιο υοπύτ ητήβαιδ ε ςίενεθσα ςυοκρασύχαπ εΣ 2 ηνίλυοσνι ε ή ςετνογάραπ ςύοκιτηβαιδιτνα ςυονε όναβ αλ
analysis of the results for overweight patients treated with metformin after failure of diet alone showed: • a significant reduction of the absolute risk of any diabetes-related complications in the metformin group (29.8 events/ 1000 patient-years) versus diet alone (43.3 events/ 1000 patients-years), p=0.0023, and versus the combined sulfonylurea and insulin monotherapy groups (40.1 events/ 1000 patients-years), p=0.0034; • a significant reduction of the absolute risk of diabetes-related mortality: metformin 7.5 events/ 1000 patient-years, diet alone 12.7 events/ 1000 patient-years, p=0.017; • a significant reduction of the absolute risk of overall mortality: metformin 13.5 events/ 1000 patient-years versus diet alone 20.6 events/ 1000 patients-years (p=0.011), and versus the combined sulfonylurea and insulin monotherapy groups 18.9 events/ 1000 patient-years, (p=0.021); • a significant reduction of the absolute risk of myocardial infarction: metformin 11 events/ 1000 patient-years, diet alone 18 events/ 1000 patient-years (p=0.01).